Non-Invasive prostate cancer therapy that is changing the way we think of
prostate cancer treatment, available to more men through new center.
CHARLOTTE, N.C., June 21 /CNW/ -- USHIFU, LLC, the exclusive distributor
of the Sonablate(R) 500 (Focus Surgery, Inc. of Indianapolis, IN) in the
Americas has opened its newest clinic in Niagara Falls, Ontario, Canada, 15
miles outside of Buffalo, New York. Niagara HIFU performed the first HIFU
procedures at the new center June 1, 2007. This is the third facility in
Ontario Canada to offer the non invasive prostate cancer treatment.
The physicians offering HIFU in the center are Ian Brown, MD FRCS(C); Jim
Lee, MD FRCS(C); Hagop Mazmanian, MD FRCS(C);and Dianne Heritz, MD FRCS(C).
All these physicians have completed training in other International HIFU
Centers and are excited about offering HIFU as a prostate cancer treatment
alternative in Niagara Falls, Ontario, Canada.
"Niagara HIFU is proud to offer High Intensity Focused Ultrasound, an
innovative choice for the treatment of prostate cancer. This option provides a
less invasive treatment with fewer side effects for patients in the battle
against prostate cancer," Brown said. "We look forward to providing state of
the art care at our new HIFU centre in Niagara Falls."
USHIFU is rapidly expanding and opening new centers throughout the
Americas. "This latest Niagara Falls transaction is consistent with our
strategy to identify and partner with top urologists in a given market. These
prestigious urologists can offer HIFU to the increasing number of men seeking
non invasive treatment options," said Stephen Puckett, Jr, Chief Executive
Officer of USHIFU. "Additionally these physicians will gain valuable
experience with the technology and ultimately become proctors for their peer
The Sonablate(R) 500 is approved for use in Canada since June 2005. The
Sonablate(R) 500 HIFU is being used in clinical trials in the United States
and has not been approved for U.S. marketing by the FDA. An application to
obtain marketing approval in the U.S. will be submitted to the FDA at the
conclusion of these clinical trials.
HIFU, which stands for High Intensity Focused Ultrasound, utilizes
focused sound waves to rapidly heat and destroy the tissue within the
prostate. The Sonablate(R) 500, the HIFU device, utilizes a transrectal probe
to apply ultrasound energy directly to the prostate without causing damage to
areas outside the gland.
Traditional treatments for prostate cancer such as surgery, radiation, or
cryotherapy (freezing) can lead to undesirable side effects such as impotence
and incontinence. International studies have shown that HIFU with the
Sonablate(R) 500 minimizes the side effects associated with other treatment
modalities and helps to preserve quality of life. In Canada, where HIFU is
available, the treatment is a one-time, outpatient procedure. It has also
been used in Canada as a salvage therapy for patients who have had other
treatments and have not been satisfied with the outcome.
For more information about Niagara HIFU or other International HIFU
Centers in the Americas, visit http://www.InternationalHIFU.com.
The Sonablate(R) 500 is developed by Focus Surgery, Inc. and manufactured
by Misonix, Inc. (Nasdaq: MSON) who also holds distribution rights in Europe.
Takai Hospital Supply Ltd. and THS International distribute the Sonablate(R)
500 in Southeast Asian and the Middle East.
For further information:
For further information: Amanda Willis of USHIFU, LLC, +1-704-332-4308,
email@example.com Web Site: http://www.internationalhifu.com